| Code | CSB-RA012145MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Gentuximab, targeting KDR (Kinase Insert Domain Receptor), also known as VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2). KDR is a critical tyrosine kinase receptor that mediates vascular endothelial growth factor signaling, playing a pivotal role in angiogenesis, vascular permeability, and endothelial cell proliferation. This receptor is extensively implicated in tumor angiogenesis, making it a significant therapeutic target in various cancers including colorectal, renal cell carcinoma, and hepatocellular carcinoma, as well as in pathological angiogenesis associated with diabetic retinopathy and age-related macular degeneration.
Gentuximab represents an investigational anti-VEGFR-2 antibody designed to inhibit angiogenic signaling pathways. This biosimilar antibody provides researchers with a valuable tool for investigating VEGF/VEGFR-2 axis mechanisms, studying tumor microenvironment dynamics, evaluating anti-angiogenic strategies, and exploring vascular biology in both oncological and non-oncological disease models. It serves as an essential reagent for preclinical studies examining angiogenesis-dependent processes and therapeutic intervention strategies.
There are currently no reviews for this product.